Noninvasive ventilation in amyotrophic lateral sclerosis: effects on sleep quality and quality of life

Abstract

Objectives: Little is known about the effects of noninvasive ventilation (NIV) on sleep quality in amyotrophic lateral sclerosis (ALS). We aim to evaluate the long-term effects of NIV on sleep quality and quality of life in patients with ALS.

Methods: In this prospective observational study, 13 ALS patients were followed for one year after initiating NIV. We evaluated sleep quality, quality of life and functional status with several questionnaires: Epworth sleepiness Scale (ESS), Pittsburg sleep quality index (PSQI), Short Form 36 Health Questionnaire (SF-36), McGill Quality of Life questionnaire (McGillQoL) and revised Amyotrophic Lateral Sclerosis Functional Rating Scale scores (ALSFRS-R).

Results: Median and interquartile range (IQR) at the start of NIV was 59 (53–65) years. The ALSFRS-R at start was 30 (24–37) (median, IQR), with three patients having severe bulbar impairment (ALSFRS-R-bulbar ≤ 9). The P_aCO₂ at start of NIV treatment was 48 (43–52) mmHg (median, IQR). During the one-year follow-up period, a significant decrease in the ALSFRS-R was observed. The impact of NIV in a short term (1 month) revealed a statistically significant decrease in ESS, decrease in total PSQI and of four PSQI subscales and improvement of almost all subscales of the McGill questionnaire. Long-term analyses (9 months to 1 year) revealed that amelioration in ESS and total PSQI was sustained.

Conclusion: We conclude that accurately titrated NIV in ALS patients can stabilize sleep quality and quality of life for at least one year, despite significant disease progression.

Keywords:

• Amyotrophic lateral sclerosis
• Noninvasive
• Ventilation
• Quality of life
• Sleep

Funding

Bart Vrijsen is funded by the Clinical Research Fund UZ Leuven and Téléthon Belgium.